NYSE:TMO
NYSE:TMOLife Sciences

Did Thermo Fisher's (TMO) New Carbon Neutral Plant Just Reinforce Its U.S. Supply Chain Advantage?

Thermo Fisher Scientific recently marked the grand opening of its 375,000-square-foot carbon neutral manufacturing center in Mebane, N.C., designed to efficiently produce over 40 million laboratory pipette tips per week and enhance U.S. supply resilience for critical research tools. At the same time, Nalgene Outdoor debuted its GloWyld collection, eco-friendly, glow-in-the-dark water bottles made with 50% recycled plastic, spotlighting ongoing innovation and sustainability efforts across...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

FDA Expands Repatha Use Might Change the Case for Investing in Amgen (AMGN)

Amgen recently announced that the U.S. Food and Drug Administration has broadened the approved use of Repatha® (evolocumab) for adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL cholesterol, regardless of prior cardiovascular disease diagnosis. This regulatory decision expands the addressable patient population for Repatha, positioning it as an option for millions of new high-risk individuals who previously were not eligible. We will now explore how this...
NasdaqGS:CMCSA
NasdaqGS:CMCSAMedia

Comcast (CMCSA): Assessing Valuation After Major Rural Broadband Expansion and MLB Content Negotiations

Kshitija Bhandaru
Comcast (CMCSA) just hit a major milestone that could shift the landscape for both its business and its stock. The company has rolled out next-generation broadband to over 32,000 homes and businesses in rural Florida, thanks to a $322 million project involving public and private partners. This kind of expansion does more than just bring high-speed internet to underserved areas; it speaks directly to Comcast’s strategy of finding growth outside saturated urban markets and increasing its...
NYSE:CLVT
NYSE:CLVTProfessional Services

How Investors Are Reacting To Clarivate (CLVT) Expanding Its R&D Solutions With Sinopec in China

Clarivate Plc recently announced it has signed agreements to deliver its academic research and intellectual property solutions to China Petrochemical Corporation (Sinopec Group), the largest oil and petrochemical products supplier in Mainland China. This partnership highlights Clarivate's growing involvement in supporting R&D objectives for leading enterprises in the Asia-Pacific region, potentially increasing its exposure to an important international market. We'll now explore how this...
NYSE:TAP
NYSE:TAPBeverage

How Historic US Alcohol Consumption Lows May Reshape Molson Coors (TAP) Investors’ Outlook

In late August 2025, reports showed that alcohol consumption in the US dropped to its lowest level since 1939, putting significant pressure on legacy brewers like Molson Coors Beverage. This development resulted in unanimous downgrades to earnings expectations from analysts, reflecting widespread concerns about Molson Coors' current business outlook and long-term strategy. We'll assess how the historic drop in US alcohol consumption is now reshaping Molson Coors' investment narrative and...
NYSE:DRD
NYSE:DRDMetals and Mining

DRDGOLD (NYSE:DRD) Valuation in Focus After Strong Earnings Growth and Higher Dividend

Kshitija Bhandaru
Here’s something for investors to chew on: DRDGOLD (NYSE:DRD) just delivered its full-year earnings and there’s no shortage of buzz. The company reported strong jumps in both sales and net income from a year ago, and that momentum has been sweetened by a higher final cash dividend. If you’re considering your next move with DRDGOLD, these signals of financial confidence are worth paying attention to, especially as the market digests what management’s bullishness means for the future. Stack...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck (MRK) Valuation in Focus After FDA Breakthrough, Pipeline Advances, and New Cost-Cutting Plans

If you have been eyeing Merck (MRK) lately, the buzz this month might feel especially relevant. After months of anticipation, the company delivered a series of pipeline updates, with some results positive and others less so. Most recently, Merck secured an FDA Breakthrough Therapy Designation for ifinatamab deruxtecan in lung cancer, initiated new studies in breast cancer, and advanced several cardiovascular programs. At the same time, Merck announced a far-reaching cost reduction plan with...